Form 4: Stryker Corp Director Caforio Receives Restricted Stock Units

Director Giovanni Caforio receives a grant of Restricted Stock Units (RSUs) from Stryker Corp.

Summary

• On May 8, 2025, Giovanni Caforio, a director of Stryker Corp, was granted 560 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Stryker Common Stock.
• The RSUs will vest 100% on the earlier of the date of the 2026 Annual Meeting of Shareholders or May 8, 2026.
• Following the transaction, Caforio directly owns 3,768 shares of Stryker common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The document does not contain any specific forward-looking statements regarding Stryker's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and prevent insider trading. Grants of restricted stock units are a typical form of executive compensation in the medical device industry.

Comparison to Industry Standards

• Stock grants are a common form of compensation for directors in publicly traded companies, including medical device companies like Medtronic, Johnson & Johnson, and Boston Scientific.
• The vesting schedule of the RSUs (vesting in approximately one year) is fairly standard.

Stakeholder Impact

• The RSU grant aligns the director's interests with shareholders, potentially leading to decisions that enhance shareholder value.
• The grant does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Stryker, Director, Giovanni Caforio, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, Equity, Compensation